Abstract
Noncoding RNAs play important regulatory roles in diverse biological processes and their misregulation might lead to different diseases, including cancer. Previous studies have reported the evolving role of miRNAs as new potential biomarkers in cancer diagnosis, prognosis, as well as predictive biomarkers of chemotherapy response or therapeutic targets. In this review, we outline the involvement of noncoding RNA in pancreatic cancer, providing an overview of known miRNAs in its diagnosis, prognosis and chemoresistance. In addition, we discuss the influence of non-coding RNAs in the metastatic behavior of pancreatic cancer, as well as the role of diet in epigenetic regulation of non-coding RNAs in cancer, which can, in turn, lead the development of new prevention’s techniques or novel targets for cancer therapy.
Keywords: Noncoding RNA, pancreatic cancer, biomarker, miRNAs, chemotherapy, epigenetic regulation.
Current Pharmaceutical Design
Title:Noncoding Rnas Emerging as Novel Biomarkers in Pancreatic Cancer
Volume: 24 Issue: 39
Author(s): Ingrid Garajová*, Rita Balsano, Chiara Tommasi and Elisa Giovannetti
Affiliation:
- Medical Oncology Unit, University Hospital of Parma, Parma,Italy
Keywords: Noncoding RNA, pancreatic cancer, biomarker, miRNAs, chemotherapy, epigenetic regulation.
Abstract: Noncoding RNAs play important regulatory roles in diverse biological processes and their misregulation might lead to different diseases, including cancer. Previous studies have reported the evolving role of miRNAs as new potential biomarkers in cancer diagnosis, prognosis, as well as predictive biomarkers of chemotherapy response or therapeutic targets. In this review, we outline the involvement of noncoding RNA in pancreatic cancer, providing an overview of known miRNAs in its diagnosis, prognosis and chemoresistance. In addition, we discuss the influence of non-coding RNAs in the metastatic behavior of pancreatic cancer, as well as the role of diet in epigenetic regulation of non-coding RNAs in cancer, which can, in turn, lead the development of new prevention’s techniques or novel targets for cancer therapy.
Export Options
About this article
Cite this article as:
Garajová Ingrid*, Balsano Rita , Tommasi Chiara and Giovannetti Elisa , Noncoding Rnas Emerging as Novel Biomarkers in Pancreatic Cancer, Current Pharmaceutical Design 2018; 24 (39) . https://dx.doi.org/10.2174/1381612825666190119125804
DOI https://dx.doi.org/10.2174/1381612825666190119125804 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Peripheral Benzodiazepine Receptor (PBR) New Insight in Cell Proliferation and Cell Differentiation Review
Current Clinical Pharmacology Combretastatin A-4 Analogs as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Cyclophosphamide and/or Anthracyclines Induced Epiphora in Breast Cancer Patients: A Rare Side-effect
Current Drug Safety Pediatric Differentiated Thyroid Cancer: When to Perform Conservative and Radical Surgery
Current Pediatric Reviews Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Bortezomib Targets the Caspase-Like Proteasome Activity in Cervical Cancer Cells, Triggering Apoptosis That Can be Enhanced by Nelfinavir
Current Cancer Drug Targets Current and Future Challenges in Primary Sjogren’s Syndrome
Current Pharmaceutical Biotechnology A Review on Extraction, Synthesis and Anticancer Activity of Betulinic Acid
Current Bioactive Compounds Non-Coding RNA in Brain Development and Disorder
Current Medicinal Chemistry Labelling and Tracking of Human Mesenchymal Stromal Cells in Preclinical Studies and Large Animal Models of Degenerative Diseases
Current Stem Cell Research & Therapy Prediction and Early Evaluation of Anticancer Therapy Response: From Imaging of Drug Efflux Pumps to Targeted Therapy Response
Current Medicinal Chemistry Impact of Sphingosine Kinase on Inflammatory Pathways in Fibroblast-Like Synoviocytes
Inflammation & Allergy - Drug Targets (Discontinued) Structural Insights for Drugs Developed for Phospholipase D Enzymes
Current Drug Discovery Technologies Cholesterol, Cardiolipin, and Mitochondria Permeabilisation
Anti-Cancer Agents in Medicinal Chemistry Signal Transduction Targets in Prostate Cancer
Current Signal Transduction Therapy On The Edge of Validation – Cancer Protease Fibroblast Activation Protein
Mini-Reviews in Medicinal Chemistry Jun Dimerization Protein 2 in Oxygen Restriction; Control of Senescence
Current Pharmaceutical Design Applications of Peptide Mimetics in Cancer
Current Medicinal Chemistry Patent Selections
Recent Patents on Drug Delivery & Formulation A Marine-based Meriolin (3-Pyrimidinylazaindole) Derivative (4ab) Targets PI3K/AKT /mTOR Pathway Inducing Cell Cycle Arrest and Apoptosis in Molt-4 Cells
Clinical Cancer Drugs